Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Children: Why, Who, and When?

Overview

Journal Clin J Am Soc Nephrol

Specialty Nephrology

Date 2023 Jan 31

PMID 36719155

Authors

Erum A Hartung

Affiliations

Soon will be listed here.

Citing Articles

Progressive Polycystic Kidney Disease in an Infant Girl With TSC2/PKD1 Contiguous Gene Syndrome.

Hashimoto K, Hayashida T, Otsubo Y, Niida Y, Dateki S Cureus. 2024; 16(8):e67800.

PMID: 39323690 PMC: 11423392. DOI: 10.7759/cureus.67800.

References

Yu A, Shen C, Landsittel D, Harris P, Torres V, Mrug M . Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int. 2018; 93(3):691-699. PMC: 5826779. DOI: 10.1016/j.kint.2017.09.027. View

Cadnapaphornchai M, Masoumi A, Strain J, McFann K, Schrier R . Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol. 2010; 6(2):369-76. PMC: 3052228. DOI: 10.2215/CJN.03780410. View

Irazabal M, Rangel L, Bergstralh E, Osborn S, Harmon A, Sundsbak J . Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2014; 26(1):160-72. PMC: 4279733. DOI: 10.1681/ASN.2013101138. View

Duicu C, Pitea A, Sasaran O, Cozea I, Man L, Banescu C . Nephrogenic diabetes insipidus in children (Review). Exp Ther Med. 2021; 22(1):746. PMC: 8138272. DOI: 10.3892/etm.2021.10178. View

De Rechter S, Breysem L, Mekahli D . Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?. Front Pediatr. 2018; 5:272. PMC: 5742347. DOI: 10.3389/fped.2017.00272. View

Mekahli D, Guay-Woodford L, Cadnapaphornchai M, Greenbaum L, Litwin M, Seeman T . Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial. Clin J Am Soc Nephrol. 2023; 18(1):36-46. PMC: 10101612. DOI: 10.2215/CJN.0000000000000022. View

Chebib F, Perrone R, Chapman A, Dahl N, Harris P, Mrug M . A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018; 29(10):2458-2470. PMC: 6171265. DOI: 10.1681/ASN.2018060590. View

Benz E, Hartung E . Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease. Pediatr Nephrol. 2021; 36(9):2639-2658. PMC: 8292447. DOI: 10.1007/s00467-020-04869-w. View

Torres V, Chapman A, Devuyst O, Gansevoort R, Grantham J, Higashihara E . Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012; 367(25):2407-18. PMC: 3760207. DOI: 10.1056/NEJMoa1205511. View

10.

Nowak K, Cadnapaphornchai M, Chonchol M, Schrier R, Gitomer B . Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2016; 44(3):171-8. PMC: 5098215. DOI: 10.1159/000448695. View